All In Biotech

Drug Trial Radar · NCT03097120

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

The Estrogen Replacement and Atherosclerosis Trial

Last checked: Nov 20, 2026Latest source record: May 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

309

Actual

Start

Jan 1995

Primary completion

Jan 2001

Study completion Jan 2001

Sponsor

Lead sponsor
Wake Forest University Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Mar 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. Methods: The investigators randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (±SD) of 3.2±0.6 years. Base-line and follow-up coronary angiograms were were analyzed by quantitative methods. Follow-up coronary angiograms were obtained after an average of 3.2 years of follow up.

Conditions

  • Heart Disease

Interventions

  • 0.625 mg of conjugated equine estrogenDrug

    one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily

  • 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetateDrug

    one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily

  • placebo tabletsDrug

    two placebo tablets daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mean minimal coronary-artery diameterTime frame: at average of 3.2 years follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.